The PD-1/PD-L1 pathway was abnormally activated in various cancers (6, 26), and anti–PD-1/PD-L1 immunotherapy has been widely used or tried in clinical trials in many solid tumors, such as lung cancer, advanced metastatic melanoma, esophagus cancer, and colorectal cancer (27, 28). Here, CD274 is linked to esophageal cancer.